Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice

Adherence to treatment with antiosteoporotic drugs is one of the most important factors contributing to their efficacy during longterm therapy. The adherence is assessed by two main lines: firstly, how long a drug is taken and, secondly, whether its dosage regimen is adhered.

Subjects and methods. The paper gives the data of a 12-month prospective follow-up study of 40 women with postmenopausal osteoporosis (OP) who initiated treatment with the biological agent denosumab.

Results and discussion. After the 12-month follow-up, the significant bone mineral density increase was 4.9% in the lumbar spine, 3.2% in the femoral neck, and 3.0% in the total hip. The previous administration of other antiosteoporotic drugs did not lower the efficiency of denosumab therapy. There were no cases of osteoporotic fractures during 1-year follow-up. 95% of the patients received two denosumab injections (an annual cycle); moreover, 90% of the women were noted to adhere to the dosage regimen. Age, marital status, level of education, time taken to reach the clinic, parental femoral fractures, a history of fractures, duration of OP, and previous therapy had no impact on treatment adherence during 12 months.

Conclusion. The one-year prospective follow-up study of the outpatients demonstrated that denosumab was an effective and safe agent for the treatment of patients with postmenopausal OP and its dosage regimen implying its rare subcutaneous administration (twice yearly) ensured the high patient adherence to therapy.

1. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38(6):922-8. doi: 10.1016/j.bone.2005.10.022.

2. Hö er A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence. 2009;3:25-30.

3. Van den Boogaard CH, BreekveldtPostma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin. 2006;22:1757-64. doi: 10.1185/030079906X132370.

4. Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23:223-31. doi: 10.1007/s00198-011-1535-z.

5. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine. 2008;75:303-10. doi: 10.1016/j.jbspin.2007.07.011.

6. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-60. doi: 10.1185/030079905X61875.

7. Hadji P, Felsenberg D, Amling M, et al. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int. 2014;25:339-47. doi: 10.1007/s00198-013-2515-2.

8. Торопцова НВ, Никитинская ОА. Приверженность лечению остеопороза у больных ревматоидным артритом. Русский медицинский журнал. 2014;(7):491-4 [Toroptsova NV, Nikitinskaya OA. Adherence to treatment of osteoporosis in patients with rheumatoid arthritis. Russkii meditsinskii zhurnal. 2014;(7):491-4 (In Russ.)].

9. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-42. doi: 10.1038/nature01658.

10. Jang G, Peterson M. Denosumab, an inhibitor of RANKL, has pharmacokinetics similar to other monoclonal antibodies. J Bone Miner Res. 2006;21 suppl 1:S190.

11. McClung MR, Lewiecki EM, Cohen SB, et al, for the AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-31. doi: 10.1056/NEJMoa044459.

12. Miller PD, Bolognese MA, Lewiecki EM, et al; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222-9. doi: 10.1016/j.bone.2008.04.007.

13. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479-89. doi: 10.1007/s00198-015-3164-4.

14. Hadji PKS, Hä ussler B, Kless T, et al. The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther. 2013;51:868-72. doi: 10.5414/CP201931.

15. Lakatos P, Toth E, Cina Z, et al. Persistence & compliance to treatment for osteoporosis in postmenopausal women in Hungary: a retrospective cohort study. Value Health. 2013;16:A567-8. doi: 10.1016/j.jval.2013.08.1516.

16. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149-57. doi: 10.1210/jc.2007-2814.

17. Cummings SR, San Martin J, McClung MR, et al, for the FREEDOM Trial. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med. 2009;361: 756-65. doi: 10.1056/NEJMoa0809493.

18. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153-61. doi: 10.1359/jbmr.0809010.

19. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72-81. doi: 10.1359/jbmr.090716.